Sort
82,697 grants matching “vaccine development”
SHIV/HIV Env-Antibody Coevolution as a Guide to Iterative Vaccine Design
$3,269,168George M Shaw · University Of Pennsylvania · P01 · FY2018 · AI
Implementing Vaccine and Treatment Evaluation Unit (VTEU) Clinical Site
$3,268,655Karen L. Kotloff · University Of Maryland Baltimore · UM1 · FY2023 · AI
NIAID SPECIMEN REPOSITORY
$3,268,542Deborah Phippard · Precision Bioservices, Inc. · N01 · FY2016 · AI
Branch Clinical Research Core
$3,264,784Ronald Gress · Division Of Basic Sciences - Nci · Z01 · FY2008 · CA
Administrative supplement to Duke G20 award
$3,264,761Herman F. Staats · Duke University · G20 · FY2022 · AI
Allogeneic and Autologous Immunotherapy for cancer and nonmalignant hematological disorders
$3,264,185Richard Childs · National Heart, Lung, And Blood Institute · ZIA · FY2022 · HL
Bridging Antibody Fc-mediated Antiviral Functions Across Humans and Non-human Primates
$3,264,079Georgia D Tomaras · Duke University · P01 · FY2016 · AI
Community Organizations for Natives: COVID-19 Epidemiology, Research, Testing, and Services (CONCERTS)
$3,261,570Dedra S Buchwald · Washington State University · U54 · FY2020 · MD
Admin-Core-001
$3,261,570Dedra S Buchwald · Washington State University · U54 · FY2020 · MD
Reagent Resource Support Program for AIDS Vaccine Development
$3,261,511Valerie Fremont · Quality Biological, Inc. · N01 · FY2024 · AI
SHIV/HIV Env-Antibody Coevolution as a Guide to Iterative Vaccine Design
$3,256,887George M Shaw · University Of Pennsylvania · P01 · FY2019 · AI
DEVELOPMENT OF A MODIFIED MRNA-BASED VACCINE FOR LASSA VIRUS
$3,253,728University Of Texas Medical Branch At Galveston · · FY2019 · Defense Health Agency
CENTERS OF EXCELLENCE FOR INFLUENZA RESEARCH AND RESPONSE: UNIVERSAL INFLUENZA RESEARCH ACTIVITIES
$3,250,144Adolfo Garcia-Sastre · Icahn School Of Medicine At Mount Sinai · N01 · FY2022 · AI
Colorado Clinical and Transational Sciences Institute
$3,249,905Ronald J Sokol · University Of Colorado Denver · UL1 · FY2021 · TR
Partners Healthcare Systems/Harvard Medical School/Boston Medical Center AIDS CTU
$3,249,397Daniel R Kuritzkes · Massachusetts General Hospital · U01 · FY2011 · AI
Vaccine-mediated cross-alphavirus protection for a live attenuated FDA licensed chikungunya virus vaccine
$3,248,576Lark L Coffey · University Of California At Davis · R01 · FY2025 · AI
Vaccine Induced Immunity in the Young and Aged
$3,245,387Rafi Ahmed · Emory University · U19 · FY2015 · AI
CHEMOKINE ADJUVANTS FOR BIOTHREAT PATHOGEN VACCINES
$3,244,665Chemocentryx, Inc. · U19 · FY2005 · AI
Multi-level Optimization of the Cervical Cancer Screening Process in Diverse Settings & Populations (METRICS)
$3,243,086Jasmin Anita Tiro · Ut Southwestern Medical Center · UM1 · FY2018 · CA
Genetic and Biochemical Approaches to Tyrosine Kinase and Lymphocyte Signaling
$3,242,965Pamela Schwartzberg · National Institute Of Allergy And Infectious Diseases · ZIA · FY2020 · AI
High resolution longitudinal immune monitoring for elucidating immune aging dynamics
$3,242,451Mark M Davis · Stanford University · P01 · FY2025 · AI
SHIV/HIV Env-Antibody Coevolution as a Guide to Iterative Vaccine Design
$3,242,287George M Shaw · University Of Pennsylvania · P01 · FY2020 · AI
Integrated Support Services Core
$3,242,259Elke C Muhlberger · Boston University Medical Campus · UC7 · FY2017 · AI
Eliciting neutralizing antibodies and B cell responses using novel HIV Env immunogens in non-human primates
$3,242,006Richard Thomas Wyatt · Scripps Research Institute, The · P01 · FY2021 · AI
Bridging Antibody Fc-mediated Antiviral Functions Across Humans and Non-human Primates
$3,241,864Georgia D Tomaras · Duke University · P01 · FY2017 · AI